MediPharm Labs Corp LABS
News
MediPharm Labs Reports Q3 2026 Results with Second Consecutive Quarter of Positive Net Income and 18% Sequential Revenue Growth
MediPharm Labs Expands Brazilian Business with Commercial Launch of ANVISA-Authorized Cannabis Extract Oil
MediPharm Labs Sets Date to Report Third Quarter 2026 Financial Results
MediPharm Labs Achieves Critical European Regulatory Milestone Supporting Commercialization of Proprietary Metered-Dose Cannabis Inhaler Platform
MediPharm Labs Appoints Greg Hunter as Chief Executive Officer and Director
MediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to Panama
Trading Information
- Previous Close Price
- CA$0.07
- Day Range
- CA$0.06–0.07
- 52-Week Range
- CA$0.06–0.10
- Bid/Ask
- CA$0.06 / CA$0.07
- Shares Outstanding
- 427.18M
- Market Cap
- CA$27.77M
- Volume/Avg
- 399,099 / 128,191
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 127
Valuation
Metric | LABS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.78 |
Price/Sales | 0.66 |
Price/Cash Flow | — |
Price/Earnings
LABS
Financial Strength
Metric | LABS |
|---|---|
Quick Ratio | 1.62 |
Current Ratio | 2.69 |
Interest Coverage | −82.92 |
Quick Ratio
LABS
Profitability
Metric | LABS |
|---|---|
Return on Assets (Normalized) | −8.40% |
Return on Equity (Normalized) | −12.21% |
Return on Invested Capital (Normalized) | −10.92% |
Return on Assets
LABS
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|!>#VKlM | LOCK|LQVT | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|bj^!Q!B | LOCK|>Qjz | $51B | |||
| Haleon PLC ADR HLN | LOCK|$zW!B?@ | LOCK|$L | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|>z&^l!#P | LOCK|Cy | $34B | |||
| Viatris Inc VTRS | LOCK|ddRKwg | LOCK|ShD | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|&% | LOCK|$% | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|Hh$hT< | LOCK|tm | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|b>s&PRx | LOCK|^b^ | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|h!^B>t | LOCK|qt!?y | $2B | |||
| Perrigo Co PLC PRGO | LOCK|H#$<&& | LOCK|^Dv | $2B |